Podcasts about alternatively

One hundred episodes! For this special occiasion, we could really only talk about one thing: super shoes. 2022 has been a banner year for next generation racing shoes with the likes of the Endorphin Pro 3, Adios Pro 3, Alphafly 2, FAST-R, and more. Nate, Matt, and DJ make their picks for most unique, most stable, and favorite racing shoes of the year so far. We're extremely excited to partner with Running Warehouse giveaway a free pair of shoes of your choice for this 100th episode! To enter, leave a comment on the YouTube podcast video answering this week's Subjective quesiton. Alternatively, you can email us at doctorsofrunningpodcast@gmail.com. The video will be out on August 12 and the giveaway will be open through August 19. To win, you must be in the US and the shoes you want must be in stock at Running Warehouse for $200 or less. The Subjective: What's your favorite racing shoe of the year so far? Chapters 0:00 - Intro 3:26 - Giveaway from Running Warehouse! 7:44 - Reflections in 100 episodes 10:29 - What's the most unique super shoe on the market 17:44 - The most stable super shoes 27:38 - Stable racing alternatives to super shoes 36:02 - DJ's favorite super shoes of 2022 so far 39:38 - Matt's picks 43:32 - Nate's racing choices 47:21 - What to look forward to for the rest of the year 53:38 - Wrap-up --- Support this podcast: https://anchor.fm/doctors-of-running/support

Good morning and happy Monday! This week we are joined by Rosemary Addis, an Enterprise Professor at the University of Melbourne. Following a successful career as a partner at a major law firm, Rosemary chose to shift to a career in social impact. She is the Founding Managing Partner of Mondiale Impact and is a recognised director and strategist, holding a portfolio of board seats. In this episode, Rosemary breaks down the recent news surrounding Mike Cannon-Brooke's attempts to block AGL, one of Australia's largest Australian energy companies, from demerging its fossil fuel arm. She provides an overview of the events and explains the motivations behind Cannon Brooke's efforts, beyond just maximizing financial gains. We discuss the broader impacts of this event, which is an exciting indicator of the general public taking climate and social action into their own hands. Rosemary speaks about the evolving social impact space in Australia, and how companies are handling the energy transition. Rosemary discusses her impressive career, including her move from corporate law to impact. She speaks about the benefits of starting off your career in a professional services firm and how it can provide a foundation for future career options in other fields. Finally, she discusses how a student who is interested in a career in social impact can best pursue it. Show your support for BoW Talks by subscribing on Apple Podcasts or following on Spotify. Alternatively you can leave a review on Apple Podcasts. Looking to join Banking on Women? Connect with us on Instagram, LinkedIn or visit our website. Looking to collaborate on a BoW Talks episode? Say hi at podcast.director@bankingonwomen.org.au Guest Recommendations: Impact Measurement and Management for the SDGs - Duke University free online course The Impact Imperative - Pamela Ryan The Biggest Bluff - Maria Konnikova

There’s a reason I haven’t watched many movies in recent months. If you missed Saturday's live broadcast of Molehill Mountain, you can watch the video replay on YouTube.  Alternatively, you can catch audio versions of the show on iTunes. Molehill Mountain streams live at 7p PST every Saturday night! Credits: Molehill Mountain is hosted by Andrew Eisen.  Music in ...Continue reading ‘Molehill Mountain Episode 298 – I May Have a Future’ »

There's a reason I haven't watched many movies in recent months. If you missed Saturday's live broadcast of Molehill Mountain, you can watch the video replay on YouTube.  Alternatively, you can catch audio versions of the show on iTunes. Molehill Mountain streams live at 7p PST every Saturday night! Credits: Molehill Mountain is hosted by Andrew Eisen.  Music in the show includes “Albino” by Brian Boyko. It is in the public domain and free to use. Molehill Mountain logo by Scott Hepting. Chat Transcript: 6:59 PMJared Knisely​start the wrong stream 6:59 PMJared Knisely​??? 7:00 PMSheekago​Hey hey 7:03 PMSheekago​I always poke fun when someone says "I slept like a baby". I'd retort with, "you woke up crying every few minutes shat and peed yourself?" 7:05 PMSheekago​Show n TELL!!! 7:06 PMSheekago​I was expecting toys... 7:07 PMSheekago​Tech toys count! 7:09 PMPhyre Lite​oooOOOooo i like it 7:09 PMSheekago​You could just have gotten a laptop with USB-C ports... 7:09 PMPhyre Lite​hello 

Note: This is the first time I've livestreamed a shiur on Facebook AND the first time I've had to strip the audio from a Facebook livestream using an audio extractor. If you notice any problems in the video or audio, please bring them to my attention! This morning (8/7/22), at The Island Synagogue (a.k.a. Shevet Achim) on Mercer Island, I gave my annual Tishah b'Av shiur, which I livestreamed on Facebook (hence, the sub-Zoom-quality video and audio). This year's focus was Kinnah #28, which dealt with the theme of nechamah (consolation) and its implications for how we relate to Tishah b'Av and the period that follows.----------מקורות:קינה כ"ח: איך אנחםרמב"ם - משנה תורה: ספר זמנים, הלכות תעניות א:א-ג; ה:אירמיהו ט:כב-כגרמב"ם - מורה הנבוכים ג:נדאיוב פרק כארב הירש - בראשית ה:כטא' שמואל ב:א-י----------The Torah content for these two weeks has been sponsored by Ariel Rachmanov, a friend and Mishlei talmid of mine. Ariel works for Keller Williams Real Estate and has generously offered to donate to the Rabbi Schneeweiss Torah Content Fund a percentage of any business that comes his way as a result of this sponsorship, resulting in a Mishleic "win, win, win" scenario for all parties involved. Ariel is based in New York but will be happy to help you meet your real estate needs in all 50 states.----------If you have questions, comments, or feedback, I would love to hear from you! Please feel free to contact me at rabbischneeweiss at gmail.----------If you've gained from what you've learned here, please consider contributing to my Patreon at www.patreon.com/rabbischneeweiss. Alternatively, if you would like to make a direct contribution to the "Rabbi Schneeweiss Torah Content Fund," my Venmo is @Matt-Schneeweiss, and my Zelle and PayPal are mattschneeweiss at gmail.com. Even a small contribution goes a long way to covering the costs of my podcasts, and will provide me with the financial freedom to produce even more Torah content for you.If you would like to sponsor a day's or a week's worth of content, or if you are interested in enlisting my services as a teacher or tutor, you can reach me at rabbischneeweiss at gmail.com. Thank you to my listeners for listening, thank you to my readers for reading, and thank you to my supporters for supporting my efforts to make Torah ideas available and accessible to everyone.----------Patreon: patreon.com/rabbischneeweissYouTube Channel: youtube.com/rabbischneeweissBlog: kolhaseridim.blogspot.com/"The Mishlei Podcast": mishlei.buzzsprout.com"The Stoic Jew" Podcast: thestoicjew.buzzsprout.com"Rambam Bekius" Podcast: rambambekius.buzzsprout.com"Machshavah Lab" Podcast: machshavahlab.buzzsprout.com"The Tefilah Podcast": tefilah.buzzsprout.comWhatsApp Group: https://chat.whatsapp.com/GEB1EPIAarsELfHWuI2k0HAmazon Wishlist: amazon.com/hz/wishlist/ls/Y72CSP86S24W?ref_=wl_sharel

The PSEi is the main index of the Philippine Stock Exchange (PSE). It is composed of a fixed basket of 30 companies, whose selection is based on a specific criteria. The PSEi provides a snapshot of the market's overall condition by gauging changes in the stock prices of select listed companies. There are six other sub-indices that provide a useful measurement of the sectoral performance, namely: Financial Index, Industrial Index, Holding Firms Index, Property Index, Services Index, and Mining & Oil Index. If you want to invest in the PSEi, you may buy FMETF, which is traded in the stock market similar to stocks. Alternatively, if you're interested to buy an S&P 500 ETF like SPY or VOO, you may use GoTrade.

Enjoy what we do? Get Value from our content? Then please consider becoming a YouTube Member.

  Vidcast:  https://youtu.be/td9JaYCpLPA   The CPSC and DeWALT have recalled DeWALT 12-inch Sliding Compound Miter Saws.  The rear safety guard on this mitre saw may detach or break creating the possibilities that the user could sustain deep lacerations from the exposed saw blade and that projectiles could strike the user or bystanders.  About 1,364,000 of these saws were sold in the US and about 118,600 were sold in Canada at Lowe's stores, The Home Depot and hardware stores nationwide, and online at Amazon.com, Lowes.com and at other websites.  Immediately stop using these recalled saws and contact DeWALT at 1-800-990-6421 for information regarding receipt of a free repair kit.  Alternatively, owners may take their saw to a DeWALT service center for a free repair.   https://www.cpsc.gov/Recalls/2022/DeWALT-Recalls-Nearly-1-4-Million-Miter-Saws-Due-to-Injury-and-Laceration-Hazards   #dewalt #mitresaw #safetyguard #lacerations #penetratingwounds #recall  

Bonjour mon petit chérubins et bienvenue a Taskmaster: The People's Podcast. This week Jackie B is tackling the thorny issue of home vs away. How do Taskmaster contestants fare when they're taken out of the comfort of the lab, study and garden and thrust in to the savage wilderness of Buckinghamshire. Lou and Jack also chat with Ryan this week who has craftily incorporated Taskmaster into his French teaching in Canada. If you're a francophile who's really likes questions in broken, questionable French then this is the interview for you.Alongside this we have another answer from one of the Andys AND a brand new section of the podcast where we pit different moments in Taskmaster history against each other to see which will come out on top. Literally what more could you want in life?If you want to share your Taskmaster obsession, whether it's talking about your favourite task, what you loved from the latest episode or that you've founded one of the top three Taskmaster fan clubs within the Artic Circle, we're all ears. You can leave a voice note on the Fanswering (it's mad that we're still going with this) machine. The number is 07810 025570. Alternatively send us an email at the address below. Your time starts... NOW!Watch Taskmaster every Thursday at 9pm on Channel 4.Get in touch with Lou and Jackfans@taskmaster.tvWatch all of Taskmaster on All 4www.channel4.com/programmes/taskmaster Visit the Taskmaster Store for all your TM goodies!taskmasterstore.comCatch up with old episodes from anywhere in the worldtaskmastersupermaxplus.vhx.tvVisit the Taskmaster YouTube Channelyoutube.com/taskmaster Taskmaster the Podcast is Produced by Ben Drayton for Avalon Television See acast.com/privacy for privacy and opt-out information.

Would you like to sponsor an episode? A series?   We'd love to hear from you : podcasts@ohr.edu   Subscribe to Ohr Somayach!    https://podcasts.ohr.edu/   00:00 Rav address two sent it questions, regarding anistanus and talmud Torah    08:30 It is said that if someone makes 3 shidduchim, they are guaranteed Olami Habo—how does this work?    13:42 Where do the traditions for tefillin designs and wrapping techniques come from?   21:37 What are the pleasures of this world that we are essentially obligated to enjoy according to the Yerushalmi?   27:52 If Judaism is meant to be authentic, why is it that in Kiruv, we offer so many fancy trips and gourmet food?   33:09 In terms of the sun being stopped for Moshe and Joshua, it says it never happened before by Joshua—how do we understand this?   35:30 What are the different opinions of taking early Shabbos?   45:03 These days, there are often discounts given by insurance companies to women and the gender is defined by what the insured person states. Would it be mutar for a biological man to say he identifies as a woman in order to pay a smaller premium?   49:57 How could two opposite statement be true?   52:38 In terms of Tu B'Av, how do we understand the gemara's reasons for a public shidduch day so to speak and how did times change?   58:56 How is it that Targum Onkelos was min HaShamyim?   1:02:29 Do we make Yam Hagadol bracha on the Pacific Ocean?   1:03:24 Why wouldn't the whole world be made Jewish such that everyone would have the maximum opportunity for closeness to Hashem?   1:07:02 if the Talmud discusses 8 genders of Judaism, what does that mean?   1:08:37 Why do we accept Kabbalah today in Halacha?   1:13:09 If I can't finish slichos, tachanun, general tefillah or the like, am I'm missing out on certain forgiveness capacity?   1:16:43 How do we relate to the destruction of the Temple if we never experienced it and why would our lowly generation be fortunate enough to have it rebuilt?    1:22:53 Why do Ashkenazim and Sephardim differ in the way they cover their eyes in Shema?   1:24:50 Kesubos is the current masechta in Daf Yomi cycle. A lot of the material discussed is about rape and other material that some may find disturbing. Can the Rav share some advice on how to approach this masechta with the right perspective. Alternatively, if learning this masechta will bother or discourage someone everyday, is it better to just learn something else?   1:30:16 How does it work that Torah is the ultimate healer but the Rambam states that one needs other outlets?   1:32:30 Why do we follow certain halachos today that some rabbanim wouldn't have approved of?   1:36:25 Rashi in Moed Katon explains the practice of the Beis Din placing a stone on someone's coffin as a זכר בעלמא of stoning someone who died while excommunicated.  If so, why do we place stones on graves today?   1:37:32 Why didn't Avraham get punished for asking for a guarantee for Israel's quality while the Meraglim did?   1:39:36 How do we view the seemingly vain descriptions of women in Ta'anis?   1:41:31 If creative acts are forbidden on Shabbos (melachos) why is intimacy permitted, isn't that the most creative act?   1:43:47 What messages was Hashem trying to convey to Eliyahu during Har HaCarmel events?     Visit us @ ohr.edu     

Drew Meredith, CFP and Owen Rask are back talking ASX Reporting Season and US stock market quarterly reports. Every week: Owen & Drew will summarise 10 key company reports. Subscribe to The Australian Investors Podcast on your favourite podcast player. (using the links above) In this ASX reporting season, Owen Rask & Drew Meredith cover the following companies. ASX shares: Pinnacle Investment Management Ltd (ASX: PNI) PlaySide Studios Ltd (ASX: PLY) Macquarie Group (ASX: MQG) Block CDI (ASX: SQ2) Australian Foundation Investment Company (ASX: AFI) or AFIC US stocks: PayPal Holdings Inc (NASDAQ: PYPL) Block CDI (NYSE: SQ) Amazon.com Inc (NASDAQ: AMZN) Apple Inc (NASDAQ: AAPL) Alphabet Inc (NASDAQ: GOOGL) Want us to cover your company? If you would like Drew and Owen to cover a company on your watchlist or in your portfolio, say g'day to Owen on Twitter. Watch the video version on the Rask Australia YouTube page. Take Owen's brand new Value Investor Program, which gives you all the tools and knowledge you need to invest successfully in companies, including valuation spreadsheets, investing checklists and ASX company case studies. Alternatively, why not take Owen's FREE investor bootcamp: bit.ly/rask-analyst Join The Intelligent Investor & save This podcast is brought to you by The Intelligent Investor, Australia's premier investment research membership service. Use the code "RASK", to get $100 off your annual membership or get a free 15-day trial (no credit card details required):

At Tech.eu, we're never ones to shy away from experimentation. And so in the spirit of being a fly on the wall at Robin and Dan's favourite Friday night spot to share a tasty beverage, we're bringing you the Drive at Five. Alternatively, the RAD (Robin and Dan) show, where we ponder what went down in European tech this past week, and try to make sense of it all.Today, RAD wax poetic about what happened, or is happening, at SoundCloud as they've announced (another) series of layoffs, auxmoney and lenders borrowing to lend, why the German government is a bit late to the game on dishing out some serious cash to native startups, and where Dan might be applying for a new job. All this and more on the Tech.eu Drive at Five

In this episode of the Maven Money Personal Finance Podcast… Andy shares shares the mindsets and behaviours of amateurs vs pros.   Links:    Humans Under Management   Andy Hart   Patreon   Leave a review!     Don't forget to check out the Maven Adviser website for more great content.   So sit back and enjoy unrivalled words of wisdom from Andy Hart - host of the UK's premier personal finance show.   Is there a topic you'd like Andy to cover? We'd love to hear from you! Contact Andy Hart directly with any comments / feedback on team@mavenadviser.com. Alternatively you can reach out on Twitter @MavenAdviser. 

In our previous episodes, we've covered the digital marketing tactics for the nation's top 3PLs and carriers—but what about the freight tech space?Freight tech arguably has a stronger focus on media, marketing, and its website so we're going to analyze some of the companies at the top so the SMBs can learn how to replicate their strategies.Freightwaves Freight Tech Top 25 of 2022Everything is Logistics is hosted by Blythe Brumleve, founder of Digital Dispatch where we help freight companies get online and grow. Check out our top shows to fix your website and fix your marketing. Alternatively, you can search by topic and check out all our past episodes of the podcast—right on our website.Connect with Blythe on Linkedin, YouTube, and TikTok

Dan & Nathan reunite to talk about one of the most head scratching SBC's of the year in Ferland Mendy plus wrap up all of the weeks other content including a striker you really should try out. We also give our predictions as to what might be left in this game cycle before FIFA 23 hits the shelves. Remember we need your help to grow our new YouTube channel, all it takes is for you to subscribe for free, and it will help more people find us! Also, if you want help improving your game please check out FUTCoaching.com and to help support the show and get a range of benefits including episodes ad-free and early, head to patreon.com/futinreview. Alternatively, please leave us a 5-star review over at Apple to help spread the word of the show, or you can also leave us a review on Spotify! --- Send in a voice message: https://anchor.fm/futinreview/message

Synopsis: This is the audio version of the 1-page article I wrote, entitled, Is it Permissible to Enjoy Learning on Tishah b'Av? I rarely write my articles about halacha, but after stating in an earlier article that Tishah b'Av used to be "the most enjoyable day of every summer," on account of the learning we'd do with Rabbi Moskowitz zt"l, I felt it would be appropriate to examine this phenomenon in light of the halachos.----------The Torah content for these two weeks has been sponsored by Ariel Rachmanov, a friend and Mishlei talmid of mine. Ariel works for Keller Williams Real Estate and has generously offered to donate to the Rabbi Schneeweiss Torah Content Fund a percentage of any business that comes his way as a result of this sponsorship, resulting in a Mishleic "win, win, win" scenario for all parties involved. Ariel is based in New York but will be happy to help you meet your real estate needs in all 50 states.----------If you have questions, comments, or feedback, I would love to hear from you! Please feel free to contact me at rabbischneeweiss at gmail.----------If you've gained from what you've learned here, please consider contributing to my Patreon at www.patreon.com/rabbischneeweiss. Alternatively, if you would like to make a direct contribution to the "Rabbi Schneeweiss Torah Content Fund," my Venmo is @Matt-Schneeweiss, and my Zelle and PayPal are mattschneeweiss at gmail.com. Even a small contribution goes a long way to covering the costs of my podcasts, and will provide me with the financial freedom to produce even more Torah content for you.If you would like to sponsor a day's or a week's worth of content, or if you are interested in enlisting my services as a teacher or tutor, you can reach me at rabbischneeweiss at gmail.com. Thank you to my listeners for listening, thank you to my readers for reading, and thank you to my supporters for supporting my efforts to make Torah ideas available and accessible to everyone.----------Patreon: patreon.com/rabbischneeweissYouTube Channel: youtube.com/rabbischneeweissBlog: kolhaseridim.blogspot.com/"The Mishlei Podcast": mishlei.buzzsprout.com"The Stoic Jew" Podcast: thestoicjew.buzzsprout.com"Rambam Bekius" Podcast: rambambekius.buzzsprout.com"Machshavah Lab" Podcast: machshavahlab.buzzsprout.com"The Tefilah Podcast": tefilah.buzzsprout.comWhatsApp Group: https://chat.whatsapp.com/GEB1EPIAarsELfHWuI2k0HAmazon Wishlist: amazon.com/hz/wishlist/ls/Y72CSP86S24W?ref_=wl_sharel

Arson is the crime of willfully and deliberately setting fire to or charring property. Though the act typically involves buildings, the term can also refer to the intentional burning of other things, such as motor vehicles, watercraft, or forests. The crime is typically classified as a felony, with instances involving a greater degree of risk to human life or property carrying a stricter penalty. Arson which results in death can be further prosecuted as manslaughter or murder. A common motive for arson is to commit insurance fraud. In such cases, a person destroys their own property by burning it and then lies about the cause in order to collect against their insurance policy. A person who commits arson is referred to as an arsonist, or a serial arsonist if committed several times. Arsonists normally use an accelerant (such as gasoline or kerosene) to ignite, propel and directionalize fires, and the detection and identification of ignitable liquid residues (ILR's) is an important part of fire investigations. Pyromania is an impulse control disorder characterized by the pathological setting of fires. Most acts of arson are not committed by pyromaniacs. Blackmail is an act of coercion using the threat of revealing or publicizing either substantially true or false information about a person or people unless certain demands are met. It is often damaging information, and it may be revealed to family members or associates rather than to the general public. These acts can also involve using threats of physical, mental or emotional harm, or of criminal prosecution, against the victim or someone close to the victim. It is normally carried out for personal gain, most commonly of position, money, or property. It is also used, sometimes by state agencies, to exert influence; this was a common Soviet practice, so much so that the term "kompromat", transliterated from Russian, is often used for compromising material used to exert control. Blackmail may also be considered a form of extortion. Although the two are generally synonymous, extortion is the taking of personal property by threat of future harm. Blackmail is the use of threat to prevent another from engaging in a lawful occupation and writing libelous letters or letters that provoke a breach of the peace, as well as use of intimidation for purposes of collecting an unpaid debt. In many jurisdictions, blackmail is a statutory offense, often criminal, carrying punitive sanctions for convicted perpetrators. Blackmail is the name of a statutory offense in the United States, England and Wales, and Australia, and has been used as a convenient way of referring to certain other offenses, but was not a term used in English law until 1968. Blackmail was originally a term from the Scottish Borders meaning payments rendered in exchange for protection from thieves and marauders. The "mail" part of blackmail derives from Middle English male meaning "rent or tribute". This tribute (male or reditus) was paid in goods or labor; hence "blackmail". Alternatively, it may be derived from two Scottish Gaelic words blathaich - to protect; and mal - tribute or payment. --- Send in a voice message: https://anchor.fm/law-school/message Support this podcast: https://anchor.fm/law-school/support

Synopsis: This is the audio version of the 1-page article I wrote, entitled, How to Make Kinnos Real, which showcases two applications of my continually evolving approach to kinnos. The Series:Part 1: The Induction of Metaphysical TraumaPart 2: The Necessity of Metaphysical Trauma for National TeshuvahPart 3: An Approach to the Blasphemy in Eichah and KinnosPart 4: EFT (Episodic Future Thinking) Training: A Summer 2022 ExperimentPart 5: The Role of Episodic Memory in the Three Weeks and Tishah b'Av----------The Torah content for these two weeks has been sponsored by Ariel Rachmanov, a friend and Mishlei talmid of mine. Ariel works for Keller Williams Real Estate and has generously offered to donate to the Rabbi Schneeweiss Torah Content Fund a percentage of any business that comes his way as a result of this sponsorship, resulting in a Mishleic "win, win, win" scenario for all parties involved. Ariel is based in New York but will be happy to help you meet your real estate needs in all 50 states.----------If you have questions, comments, or feedback, I would love to hear from you! Please feel free to contact me at rabbischneeweiss at gmail.----------If you've gained from what you've learned here, please consider contributing to my Patreon at www.patreon.com/rabbischneeweiss. Alternatively, if you would like to make a direct contribution to the "Rabbi Schneeweiss Torah Content Fund," my Venmo is @Matt-Schneeweiss, and my Zelle and PayPal are mattschneeweiss at gmail.com. Even a small contribution goes a long way to covering the costs of my podcasts, and will provide me with the financial freedom to produce even more Torah content for you.If you would like to sponsor a day's or a week's worth of content, or if you are interested in enlisting my services as a teacher or tutor, you can reach me at rabbischneeweiss at gmail.com. Thank you to my listeners for listening, thank you to my readers for reading, and thank you to my supporters for supporting my efforts to make Torah ideas available and accessible to everyone.----------Patreon: patreon.com/rabbischneeweissYouTube Channel: youtube.com/rabbischneeweissBlog: kolhaseridim.blogspot.com/"The Mishlei Podcast": mishlei.buzzsprout.com"The Stoic Jew" Podcast: thestoicjew.buzzsprout.com"Rambam Bekius" Podcast: rambambekius.buzzsprout.com"Machshavah Lab" Podcast: machshavahlab.buzzsprout.com"The Tefilah Podcast": tefilah.buzzsprout.comWhatsApp Group: https://chat.whatsapp.com/GEB1EPIAarsELfHWuI2k0HAmazon Wishlist: amazon.com/hz/wishlist/ls/Y72CSP86S24W?re

In this episode of Japan Memo, Robert Ward and Yuka Koshino host Dr Tsuruoka Michito, Associate Professor at the Faculty of Policy Management at Keio University, as well as Senior Associate Fellow at the Centre for Security, Diplomacy and Strategy (CSDS) at the Brussels School of Governance, and Senior Fellow at the Tokyo Foundation for Policy Research.Robert, Yuka, and Tsuruoka-sensei unpack the background context of growing Japan-NATO relations, the 2022 Madrid Summit, the implications of deepening Japan-NATO engagement, and opportunities and roadblocks to increased Japan-NATO cooperation. Topics discussed include:Former Prime Minister Abe Shinzo's legacy for Japan-NATO relations The significance of Prime Minister Kishida's participation in the 2022 Madrid Summit Japan and NATO's expectations on the trajectory of their relationshipPractical avenues of cooperation for Japan and NATO to engage inThe role of the US in streamlining Japan-NATO cooperation The following literature is recommended by our guest to gain a clearer picture of Japan and Japanese society today:Our guest recommends tabloid papers or weekly magazines such as “Shukan Bunchun” (週刊文春), “Shukan Shinchou” (週刊新潮), or sports and entertainment tabloids such as “Sankei Sports” (サンケイスポーツ)Alternatively, “Variety” TV programmes in the form of morning or evening shows also illuminate Japanese viewpoints on domestic or international issues. We hope you enjoy the episode and please follow, rate, and subscribe to Japan Memo on the podcast platform of your choice.Date of Recording: 19 July 2022Japan Memo is recorded and produced at the IISS in London. See acast.com/privacy for privacy and opt-out information.

For a lot of us who work in freight, we know about the relationship between carriers, shippers, and brokers. But very few talk about the government contracting side of freight--which can be incredibly demanding but also lucrative.Joining us for a second time is the amazing Melanie Patterson who is the Founder and Managing Director of Team Integrity Knowledge Center she's going to break down the in's and out's of the government contracting side of freight and how carriers can get in on the action. Connect with Melanie Patterson on Linkedin Follow Team Integrity Knowledge Center on Instagram and their website. Everything is Logistics is hosted by Blythe Brumleve, founder of Digital Dispatch where we help freight companies get online and grow. Check out our top shows to fix your website and fix your marketing. Alternatively, you can search by topic and check out all our past episodes of the podcast—right on our website.Connect with Blythe on Linkedin, YouTube, and TikTok

Synopsis: This is the audio version of the 1-page article I wrote, entitled, Wishful Thinking and Prophetic Interpretation, in which we examine a machlokess between Ibn Kaspi and Rashi on how to learn Neviim and its ramifications for those who attempt to uncover the true meanings of their prophecies today.----------The Torah content for these two weeks has been sponsored by Ariel Rachmanov, a friend and Mishlei talmid of mine. Ariel works for Keller Williams Real Estate and has generously offered to donate to the Rabbi Schneeweiss Torah Content Fund a percentage of any business that comes his way as a result of this sponsorship, resulting in a Mishleic "win, win, win" scenario for all parties involved. Ariel is based in New York but will be happy to help you meet your real estate needs in all 50 states.----------If you have questions, comments, or feedback, I would love to hear from you! Please feel free to contact me at rabbischneeweiss at gmail.----------If you've gained from what you've learned here, please consider contributing to my Patreon at www.patreon.com/rabbischneeweiss. Alternatively, if you would like to make a direct contribution to the "Rabbi Schneeweiss Torah Content Fund," my Venmo is @Matt-Schneeweiss, and my Zelle and PayPal are mattschneeweiss at gmail.com. Even a small contribution goes a long way to covering the costs of my podcasts, and will provide me with the financial freedom to produce even more Torah content for you.If you would like to sponsor a day's or a week's worth of content, or if you are interested in enlisting my services as a teacher or tutor, you can reach me at rabbischneeweiss at gmail.com. Thank you to my listeners for listening, thank you to my readers for reading, and thank you to my supporters for supporting my efforts to make Torah ideas available and accessible to everyone.----------Patreon: patreon.com/rabbischneeweissYouTube Channel: youtube.com/rabbischneeweissBlog: kolhaseridim.blogspot.com/"The Mishlei Podcast": mishlei.buzzsprout.com"The Stoic Jew" Podcast: thestoicjew.buzzsprout.com"Rambam Bekius" Podcast: rambambekius.buzzsprout.com"Machshavah Lab" Podcast: machshavahlab.buzzsprout.com"The Tefilah Podcast": tefilah.buzzsprout.comWhatsApp Group: https://chat.whatsapp.com/GEB1EPIAarsELfHWuI2k0HAmazon Wishlist: amazon.com/hz/wishlist/ls/Y72CSP86S24W?ref_=wl_sharel

Our relationships with the people around us, whether family, friends, partners or work colleagues, are important for our emotional health and practical support. But sometimes MS can feel like a barrier to those relationships, making it harder to maintain the ones that matter to us or develop new ones in the future. So today we are going to dive into some of those issues. We will be joined by Billy from shift. MS who lives with MS himself and Flora from or MS Trust helpline.  Episode notes: - Relationships and family life - Information from the MS Trust: mstrust.org.uk/life-ms/relationships-and-family-life - Talking with fiends and family about MS - Information from the MS Trust: mstrust.org.uk/life-ms/family-and-relationships/talking-friends-and-family -Information for carers - Information from the MS Trust:mstrust.org.uk/life-ms/family-and-relationships/information-carers - MS Trust booklet; Someone I know has MS: shop.mstrust.org.uk/publications/someone-i-know-has-ms/- MS Trust booklet; Kid's guide to MS: shop.mstrust.org.uk/publications/kids-guide-to-ms/ - Caring for someone with MS - Podcast from the MS Trust: mstrust.org.uk/resources/podcasts-ms-trust/caring-someone-ms -MS Trust Facebook Group: facebook.com/groups/multiplesclerosistrust -Shift.ms -a social network and community for people with MS: shift.ms -Shift.ms Buddy system: shift.ms/the-buddy-network -Relationships and MS - webinar from MS Society Ireland:  youtube.com/watch?v=zcp92YezvZM Next episode Our next podcast will be on disease modifying Drugs and MS, where we are hoping to dive into the world of MS treatments and answer some questions on the subject that you may have. If you have anything to say about DMT's or that you want to ask about we would love to hear from you and your comment may even be featured on the episode! (it can remain totally anonymous)  You can drop us a voice note or message via WhatsApp on 07458303326. Alternatively, you can email mystory@mstrust.org.uk. It can be totally anonymous.WhatsApp messages aren't monitored by our MS Helpline team so if you've got a question about life with MS that needs answering, please contact them directly on 0800 032 38 39 or email ask@mstrust.org.uk.

This week, please join authors Paul Ridker and Eric Van Belle, editorialist Robert Harrington, and Guest Editor Allan Jaffe as they discuss the original research articles "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy" and “Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Cohort” and the editorial "Trials and Tribulations of Randomized Clinical Trials." Dr. Carolyn Lam:             Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the Journal and its editors. We're your co-hosts. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center, and Duke National University of Singapore. Dr. Greg Hundley:           And I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Dr. Carolyn Lam:             It's double feature time Greg. We've got two totally unique and interesting papers that we'll be discussing. The first, a biomarker substudy from the REDUCE-IT trial, that is looking at the effects of randomized treatment with icosapent ethyl, versus a mineral oil comparator, on inflammatory biomarkers. Now, don't use roll your eyes at me, because I'm telling you, this has results that you may not expect, and very, very important clinical implications, and implications for clinical trials. The second paper, very much up your alley, Greg, is a prospective MRI study of cerebral microbleeds during TAVR. But okay, enough now to whet your appetite, let's now just first grab coffees, and discuss the other papers and the issue, shall we? Dr. Greg Hundley:           You bet, Carolyn. And how about if I go first? Dr. Carolyn Lam:             Please. Dr. Greg Hundley:           So, Carolyn, my first paper comes from a group of investigators led by Dr. Araz Rawshani from the Institute of Medicine, and it included 715,143 patients with diabetes, registered in the Swedish National Diabetes Register, and compared them with over two million match controls, randomly selected from the general population, to determine the role of diabetes in the development of valvular heart disease, and particularly, the relation with risk factor control. Dr. Carolyn Lam:             Huh? Interesting, diabetes and valve disease. All right. What did they find, Greg? Dr. Greg Hundley:           Right, Carolyn. So they found, that individuals with type one and two diabetes, have greater risk for stenotic lesions. Whereas, risk for valvular regurgitation was lower in type two diabetes. Patients with well controlled cardiovascular risk factors, continued to display higher risk for valvular stenosis, without a clear stepwise decrease in risk between various degrees of risk factor control. So Carolyn, diabetes and a link with valvular heart disease. Dr. Carolyn Lam:             Wow. Really interesting, Greg. Thanks. Well, the next paper is a preclinical study with really interesting clinical implications. Now, we know the human heart has limited capacity to regenerate new cardiomyocytes, and that this capacity declines with age. Now, because loss of cardiomyocytes may contribute to heart failure, it is important to explore how stimulating endogenous cardiac regeneration, to favorably shift the balance between loss of cardiomyocytes and birth of new cardiomyocytes, occurs in the aged heart. Now, these authors, Doctors Rosenzweig, from Massachusetts General Hospital, and Dr. Lee from Harvard University and colleagues, previously showed that cardiomyogenesis can be activated by, guess what? Exercise in the young adult mouse heart. However, whether exercise also induces cardiomyogenesis in aged hearts, however, is not yet known. So in today's paper, the authors aim to investigate the effect of exercise on generation of new cardiomyocytes in the aged heart. And here, we're talking about 20 month old mice, who were subjected to an eight week voluntary running protocol, and age matched sedentary animals who served as controls. Dr. Greg Hundley:           Wow, Carolyn. Really interesting evaluation of exercise on cardiomyogenesis. So what did they find? Dr. Carolyn Lam:             Endogenous cardiomyogenesis can be stimulated by exercise in aged hearts. Comparative global transcriptional analysis further revealed, that exercise and age specific changes occurred in gene programs. The regulator of calcineurin RCAN1.4 was specifically found to be induced with exercise in aged hearts, and was accompanied by reduced calcineurin activity. So what's a take-home message? Exercise induced cardiomyogenesis may counter the increased cardiomyocyte loss and reduced cardio myogenic capacity in elderly patients. Dr. Greg Hundley:           Great, Carolyn. Well from the mail bag, there's an exchange of letters to the editor from Professor Zhou and Veith regarding a prior letter to the editor from Professor Jin and associates, pertaining to the previously published article “SPARC, A Novel Regulator of Vascular Cell Function in Pulmonary Hypertension.” And also, there's a Perspective piece, from Professor Mentz entitled, “Catastrophic Disruptions in Clinical Trials.” Dr. Carolyn Lam:             There's also a Research Letter by Dr. Kumar on [entitled] “von Willebrand Factor Is Produced Exclusively by Endothelium, Not Neointima, in Occlusive Vascular Lesions in Both Pulmonary Hypertension and Atherosclerosis.” There's also this beautiful tour of Cardiology News from the literature, from Tracy Hampton, which ranges from a study linking COVID-19 to higher long term cardiovascular risks, which was published in Nature Med, to uncovering alternative metabolic pathways involving cell fate transitions, published in Nature, to designing an autonomous biohybrid fish, from human stem cell derived cardiac muscle cells, that was published in Science. Wow. Isn't that amazing, Greg? Well, let's get on now though, to our two feature papers. Shall we? Dr. Greg Hundley:           You bet. Welcome listeners, to these two feature discussions on this particular day. And our first feature today, we have with us Dr. Paul Ridker, from Brigham and Women's Hospital in Boston, Massachusetts. Dr. Bob Harrington, from Stanford University in California. And also, Dr. Allan Jaffe, from Rochester, Minnesota. Welcome to you all. And Paul, we're going to start for you. Can you describe for us, the background information that really went into the construct of your study, and what was the hypothesis that you wanted to address? Dr. Paul Ridker: Sure, Greg. So first of all, my thanks to the AHA and the Circulation for publishing this paper, we always want to support the AHA, and we're delighted to be here today for these podcasts. The field of omega-3 fatty acids has been a complicated one for a long time. Epidemiology suggested that, fish consumption would lower cardiovascular risk, and there was a number of trials done. And my friend and colleague here at the Brigham, Deepak Bhatt, was the lead of a very big trial, called REDUCE-IT. Some 8,000 plus patients who received EPA alone, and they got a terrific result. A 25% reduction in their primary endpoint. And this was a New England Journal paper, back in 2019 or so. But another friend of mine, Steve Nicholls, ran another large trial of a combination of eicosapentaenoic acid, or EPA, plus docosahexaenoic acid that's DHA called STRENGTH. And that one showed, really, no benefit. And so, there's been some controversy out there. In any event, when Deepak and his colleagues published their original paper, they said it's interesting, because they got this big risk reduction, but it wasn't apparently due to the triglyceride lowering of the drug. And so, my interest, as many people know, has largely been in inflammation biology. And so we said, well maybe we should just do a test. Well, we said, we'll measure a number of biomarkers that we know were associated with atherosclerosis, some inflammatory, some with coagulation. And so, that was the core hypothesis, was simply to look at some other markers, and see what we might learn. And sometimes, you learn things that you didn't expect. And I think, that goes to the heart of what complicated clinical trials are all about. And I'd also say perhaps, what the roles of surrogate endpoints are, as compared to hard clinical endpoints, and things that make this whole field kind of interesting. Dr. Greg Hundley:           Right. Very nice, Paul. So you mentioned REDUCE-IT, so describe a little bit more for your study. What was the study population, and what was your study design? Dr. Paul Ridker: We were fortunate enough to work with REDUCE-IT investigators, to use their biobank. They had put together, again, it's 8,000 plus patients. I think, it was two thirds secondary prevention, one third primary prevention. And when they received the combination of EPA and DHA, as I said earlier, they had about a 25% reduction in the risk of their primary endpoint, which was cardiovascular death, nonfatal AMI, nonfatal stroke, coronary revascularization, and the like. What we did is, we basically said, "Okay, since the mechanism was uncertain, why don't we go ahead and measure a series of biomarkers?" Things that a lot of us are interested in, homocysteine, LPLa, oxidized LDL, my own interest in inflammation. We measured, IL-1β, we measured, IL-6, we measured CRP. We measured another molecule, Lp-PLA2, that people have been interested in. And the hypothesis, of course, was to see what the drug did, as compared to the comparator did. And the findings were interesting to us, in that, to simplify them, the actual icosapent ethyl arm didn't do much to most of those biomarkers, very little change. But the mineral oil comparator arm had some small to modest effects on all those biomarkers, all of which went up again. Now, some of these effects are pretty small, two to 3% for things homocystine, LPLa. Others were moderate, 10 to 20% increases in oxidized LDL, Lp-PLA2. And the inflammatory markers went up about 25%, sometimes, even a little more. So it's complicated. It's important to point out, that these changes on an absolute scale are relatively small. On a percent scale, they're different. The REDUCE-IT investigators themselves, to their credit, had earlier published that, they saw some increase in LDL cholesterol as well, about 10, 11% in those who had received the mineral oil comparator. So it's not exactly what we thought we were going to find, I guess, is the simplest way to express it. Dr. Greg Hundley:           Very nice. And so, describe for us just a little bit more, any differences in men and women, and what about age? Or for example, premenopausal, postmenopausal women. Dr. Paul Ridker: No, the effects were quite consistent across all various subgroups. It's a very large study. There were, again, 8,000 patients, lots of blood samples been drawn. And I should again, commend the REDUCE-IT investigators, for allowing us to do this work with them. And again, as I point out, sometimes you find things out that weren't what you expected. And the hard part, I was glad this got tossed over with Dr. Harrington, is sort to figure out well, what's it really mean? Because again, as a clinical trial list, I will say, my instincts are to trust the primary endpoint of the trial. That's what they did. They're going to go out and lower heart attacks and strokes. And then, here we are a couple years later, trying to figure out what the mechanism might be, and just came across some puzzling results. Dr. Greg Hundley:           Very nice. Well, next listeners, we're going to turn to the editor that actually processed this manuscript, Dr. Allan Jaffe. Allan, what drew you to this particular article? Dr. Allan Jaffe:   Well, I was asked to be a guest editor this week, by the Journal, because of some conflicts that were intrinsic to the editorial board. And since I have an interest in biomarkers, and had for a long time, it made perfect sense for me to become involved. I was particularly interested in this particular area, because I was aware that there were these two trials that had found different endpoints, and that there were some controversy as to what the mechanisms might be by which these effects could occur. And so I was pleased to get involved. And I think it's a compliment to the REDUCE-IT investigators, and to Dr. Ridker, that they were willing to put the data out there so that everybody could see it. And we could then begin to look. So it was of interest to me. I thought it was important to the field, to get really good reviewers who would be, make sure that the data that would eventually be published was clear, so that readers would understand it. And so that, at the end, we'd be able to at least, come to some conclusions that we could end up having an expert in clinical trials. And I thought about Bob Harrington, right from the beginning, might be able to comment on. Dr. Greg Hundley:           Very nice. Well, Bob he's setting you up here nicely, both Paul and Allan, to really help us put these results in perspective with other studies that have been performed in this space. What are your thoughts? Dr. Robert Harrington:   So first off, Greg, thanks for having me. And Allan, thanks for inviting me to review and comment on the paper. As both Allan and Paul have indicated, that I've spent the last 30 plus years doing clinical trials of all sizes. Very small, where we try to understand mechanisms, and very large, where what we're trying to understand is clinical outcomes. And I've been intrigued in this field, because of the inconsistency of the data across the field. Where in some trials, Paul had indicated this STRENGTH, there seemed to be no effect of omega-3 fatty acids, and in REDUCE-IT, there was quite a pronounced effect of the test agent. And so, when one sees discordance in a field, one tries to understand, well, why might that be? And so in the editorial, I took the position that, well, what are we trying to do in clinical trials? And in outcomes trials, we're trying to figure out what matters to patients. Do they live longer? Do they feel better? Do they avoid bad stuff happening to them? Like having to undergo revascularization procedure. So you're trying to do things that are really clinically meaningful, but that doesn't say that you're also not trying to understand mechanism. And as Allan said, there have been some questions raised. And so, trying to understand mechanism in the edit in trials can be quite useful, not just to understand that trial results, but to really form hypothesis for a field going forward. And so, I took the approach of, we learn things from different trials, and sometimes we learn things in the same trial. Meaning that, there's mechanistic work embedded in the large trial. One of the most famous examples of this, in the GUSTO trial 30 years ago, we learned through the mechanistic substudy, that it was rapid reprofusion TIMI-3 establishment of TIMI-3 flow, that really explained the difference between TPA and streptokinase. So I was very intrigued by how we might use these data to explore the results. And I find the findings fascinating, as Paul said. It is complicated, but it raises a really fundamental issue in clinical trials. There's an assumption in a placebo control trial, that because randomization is allowing you to balance everything, except for the randomized treatment groups, and therefore, that comparison has causal information in it. There's an underlying assumption that's really important. And that is, that the placebo is inert. That it has no biological effect of its own. Well, that assumption was violated here. The placebo is not inert in this clinical trial. Now, the investigators, I think to their credit, have said, "Well, this is small, probably doesn't matter." And that might be right, but it also may be wrong. And you can't just say, well, it doesn't matter, these are small effects. As Paul said, some of the effects are small, some are medium, some are large. So what explains it? And I made a point in the editorial, you could model all of this. If you get 5% of this, and 10% of this, and 20% of this, you could make some assumptions and say, well, the magnitude of the benefit was so great that it couldn't have been overcome by this. But that's just modeling, and there's uncertainty. So for me, as a trialist, and somebody who really believes in using evidence to guide practice and to guide public policy, I think there's uncertainty here. It's likely that the treatment effect is not as large as was observed, but how large is it? And how large is important? And how large might we want to consider to put into our practice guidelines? I think all of those open questions, particularly in a field where there is inconsistency across trials, in terms of the observation of the outcome. So my conclusion is, we need more work. We need another trial, if we really want to understand this. And we need to use an inert placebo, to really understand what the contribution was. I'd like nothing better to see that it didn't matter. But I can't say that it doesn't matter because I don't know. Dr. Greg Hundley:           Well, listeners, boy, we've got kind of some interest here in that an unexpected result. So Paul, it's nice doing an interview like this listeners, because each speaker sets up the next one. Paul, Bob is saying, well, what should we do next to clarify the results here? So maybe we'll go through each of you, and start with Paul. Just describe for us, what do you think is the next study that we need to perform? Dr. Paul Ridker: Well, Greg, it's a really interesting issue. We saw it, as authors, to write as neutral a paper as we could possibly write, and sort of do our academic job and say, here are the data. And I think we did it that way because, we don't really know what the interpretation should be. On the one hand, you have a very big beneficial result, which is great for patients. And there's a prior clinical trial called JELIS, which was open label, the same drug, and also got a large benefit. And we were trying to figure out mechanism. That being said, as Bob pointed out, I think what we stumbled into is some level of uncertainty. And the question is, how uncertain would it be, and does it matter in the big picture? Allan was interesting, because the Journal asked us to use the word comparator, rather than placebo. Now this was designed as a placebo controlled trial, but our paper uses the word comparator, because of the possibility, that as Bob Harrington points out, it may not be totally inert. So the writing of this was quite carefully done. I think, at the end of the day, my REDUCE-IT colleagues, who I have great respect for, and really worked terribly hard to do the main trial, understandably feel, that the trial would've showed, and I have a lot of sympathy for that, because it's the hard endpoints we should go with. On the other hand, I have sympathy with the idea that it never hurts to have more data. And if there could be a way to have a second trial, and I might change the population a little bit, maybe I'd do it in true primary prevention. This was one third primary prevention. My colleague, Joanne Manson had done her, she had a trial where they showed some potential benefit in the black populations. Maybe you might over sample some minority groups. But just the pragmatic issues here, make it tough to have a second trial. And so, uncertainty is just part of what we, as physicians, have to learn to live with. Dr. Greg Hundley:           Allan, turning to you. What do you think is a next study to perform in this space? Dr. Allan Jaffe:   Well, I think what Paul has said is correct. That it would be very hard to generate enthusiasm funding for a large trial. But it might not be nearly as difficult to begin to explore the effects of the mineral oil comparator, versus the active agent, versus perhaps, another potential placebo, and see over time what happens in primary prevention patients, as a way of beginning to put some context around what these results might mean. So for example, it could turn out that, the active agent actually kept the values from rising as they normally would've, and mineral oil had no effect at all. Alternatively, mineral oil may well have been a negative. It had a negative effect. And I think, those are the sorts of questions that could be explored reasonably in the short term, without doing another multimillion dollar randomized trial. Dr. Greg Hundley:           And Bob, your thoughts. Dr. Robert Harrington:   Well, and I mentioned this in the editorial, Greg. I didn't make my recommendation lightly. I know that these trials are expensive. I know these trials take a great deal of time, a great deal of energy. And I know that the REDUCE-IT investigators worked enormously hard over the years to get this done. So I don't say tritely, "Oh, just do another trial." But if you think about the magnitude of the public health issue here, there are millions of people to who this kind of therapy might apply globally. And so, shouldn't we be more certain than less certain, if we want to include it, for example, in ACC/AHA guidelines? I would say, the answer to that is yes. And so, I think of it as, okay, let's make some assumptions. Let's assume, that the effect that was observed in JELIS and REDUCE-IT, is the true effect. That's ground truth. Well, there are different study designs one might think about, from an analytic perspective, using Bayesian statistics, as opposed to frequency statistics. One might think about an intense interim analysis plan, to understand where the data are going, and be able to pull in the prior data for evaluation. I would advise getting a smart group of people together, who spend their lives thinking about trials in the atherosclerotic space, and the REDUCE-IT team is pretty darn good, and say, "How could we do this efficiently?" I do think, there's enough uncertainty that it would be ethical, from an equipoise perspective, to include high risk patients in a second evaluation, because we do have uncertainty. And if we really want to nail this down, I think we could look at high risk patients with hypertriglyceridemia, and try to use some interesting design issues, and some interesting analytical issues, to try to reduce the sample size, lot of attention in interim analyses, to try to answer the question. I'd like, as I said, nothing better to say, "Oh look, REDUCE-IT was the truth." This next trial is consistent. That'd be, to me, a terrific outcome of this. On the other hand, if you said to me, "Well, the effect's not 25%, it's more in the 15% range." Well, maybe then we think about how we apply it to our patients a little differently, maybe a little more cautiously. So I don't make the recommendation lightly, as I said, but I do think that there are some conversations that could be had, being respectful of the effort and the expense that goes into these kind of things. To try to answer the question efficiently. Dr. Greg Hundley:           Very nice. Well listeners, we want thank Dr. Paul Ridker, from Brigham and Women's Hospital, Dr. Bob Harrington from Stanford University, Dr. Allan Jaffe, from the Mayo Clinic, for bringing us the results of a substudy of the REDUCE-IT trial, that assessed a variety of serum biomarkers, pertaining to systemic inflammation, and highlighting uncertainty around the mechanism regarding the efficacy of icosapent ethyl, that's been used previously for primary or secondary prevention of cardiovascular events. And next listeners, we are going to move to our second feature discussion and review some data pertaining to microbleeds in the central nervous system, during and after TAVR procedures. Welcome listeners, to our second feature discussion on this August 2nd. And we are going to explore some of the world of TAVR and its potential complications. And we have with us today, Dr. Eric Van Belle, from Lille, France. And also, Dr. Manos Brilakis, from Minneapolis, Minnesota. Welcome gentlemen. And Eric, we'll start with you. Can you describe for us a little, the background information that you use to assemble and construct your study, and describe, or list for us, the hypothesis that you wanted to address? Dr. Eric Van Belle:           Yes. Thanks a lot for the question. So we knew for many years, that some of the complication of the TAVR procedure relate to the brain. And it has been described by many others, that there were some complication in the brain of patient undergoing TAVR. And there was no previous investigation on potential bleeding or microbleeding in this population. And on the other side, there are previous publication on, of course, initially chronic microbleeding, in patient with some of, let's say, disease in the brain, but also, a possibility of acute microbleeding. And especially, in some interesting population relating to the TAVR feed, that is patient with valve disease, patient with endocarditis, or patient with assist device. In this population, microbleedings, acute microbleeding, have been described. And what is interesting, if you look at all these populations, these are population in which the Von Willebrand factor has been impacted and modified, and could be one of the reason of the microbleeding. And one of the similar feature of the patient with aortic stenosis that undergo TAVI, or TAVR, that are patient with indeed also, this kind of Von Willebrand disease. So if we put everything together that is previously, we only looked at antibody complication in those population, and that Von Willebrand disease, which is present in patient with aortic valve stenosis, could promote a bleeding, in particular, bleeding in the brain. We decided to look at the potential appearance of microbleeding, in patient undergoing TAVR procedure. Dr. Greg Hundley:           Very nice. And Eric, can you describe for us, your study design, and who was your study population? Dr. Eric Van Belle:           Yes. So basically, the study population is a basic population of patient undergoing TAVI. Just to make sure that one of the difficulty of this study, was to conduct and perform an MRI, a brain MRI, before the procedure, and as short as possible after the procedure, within three days, which is logistically challenging. And also, to make sure that we keep most of the population to undergo the MRI, we had to exclude patient with a high risk of pacemaker, or patient with pacemaker that could not undergo the MRI. But basically, without this, it's just a regular population. And if we indeed, compare to some of the previous work I was mentioning, about describing the acute MRI, it was important for us to make sure, or to be as sure as we could get, that indeed, this microbleeding, if we observe them, could be related to the procedure. And it means that, the MRI, after the procedure, should be done as short as possible. And also, that an MRI, a baseline MRI, should be performed. Because we know, that in this population, you could have some microbleedings also observed before starting the procedure. Dr. Greg Hundley:           So a cohort study design where MRIs are performed before, and then very soon after, TAVR procedures. So Eric, what did you find? Dr. Eric Van Belle:           So what we observed, the first thing that we confirmed was indeed, that in this population of that age, that is patient around 80 years old, when we do the baseline MRI, you find in about one out of four patients already, some microbleedings. And this was expected, and it is very similar to what is expected in this kind of population. But what was indeed more striking, that when we repeated the MRI after three days, we observed another 23% of patient with a new microbleedings that were observed. This is indeed the most important observation. What was also important that, the patient with microbleedings, and the location of the microbleedings, were not related to the cerebellum brain, because indeed we could observe some cerebellum arise in this population, as it is expected. And there was no relation between the two. So it's also, an important observation, suggesting that this microbleeding are not hemorrhagic transformation of cerebellum brain, for instance. And we also observed that, the risk of microbleeding, or the chance to observe the microbleeding, was increased when the procedure was longer. And also, when the total duration of anticoagulation was longer, we also observed that, when the procedure was, when we used protamine at the end of the procedure, the risk of microbleeding was less. And also, importantly, the status of the Von Willebrand factor, and indeed, an alteration of the multimer of Von Willebrand factor, was also associated with the risk of microbleeding in this population. Dr. Greg Hundley:           Very nice. So in this cohort of 84 individuals, average age around 80, undergoing TAVR procedure, and about 50/50 men and women, you had several factors. Prior history of bleeding, amount of heparin, absence of protamine, all indicating a higher risk of these microbleeds. So very practical information. Well, Manos, you have many papers come across your desk. What attracted you to this particular paper? And then secondly, how do we put these results really, in the context of maybe other complications that can occur during or after TAVR procedures? Dr. Emmanouil Brilakis: Yes, thanks so much, Greg. And also, congratulations Eric, for a wonderful paper, and thanks for sending it to circulation. I think, with increasing the number of targets, as you know, TAVR now is becoming the dominant mode for treating severe aortic stenosis. Safety is of paramount importance. And even though there's been a lot of progress, we still have issues with the safety of the procedure. So understanding how can make it safer is very important. And I think, what was unique in this paper, again, congratulations for creating this study, is that it opens a new frontier. We worry about stroke. We're all very worried about the stroke, and having the patient have a permanent neurologic damage during the procedure. But there may be more to it than the classic embolic stroke. And I think, this study opens actually, a new frontier with the micro cerebral bleeds. Now we don't completely understand, despite the study, we don't understand the functional significance from this. And I think, that's one of the areas that will need further research. But I think, trying to understand what causes them, and preventing those microbleeds, would have a very important role in the future, for making TAVR even safer than it is. Dr. Greg Hundley:           Very nice. Well, Manos, you really lead us into the kind of the next question. So Eric, what do you see as the next study to be performed in this sphere of research? Dr. Eric Van Belle:           Again, to me, and to follow with the comment of Manos, we need to include, I would say, to solve two questions. We have to solve the question of, what could really impact these microbleedings. And what would be the impact of this microbleeding on the long term outcome of this patient? So it's means that we have to set, as part of the studies that we will design, potentially studies on aortic immolation. Or let's say for instance, we could investigate the role of protamine. It has been suggested that protamine could be something interesting, so it could be tested as part of a randomized study. But this means that, as part of such randomized study on the use of protamine, for instance, you would include a last cohort of patients with MRI after the procedure. And also, a long term follow of the neurological complication, which indeed, is the missing part of our current study. We would need to have a much larger cohort of patients, to be able to reconnect the neurological outcome to the MRI outcome, and also to include this. So let's say, for me, one of the studies we would be interested to perform, is to conduct a study on the use of protamine, which is very simple, randomized, yes or no, and includes brain MRI in this population, as a systematic investigation, which is difficult to conduct. You have to know that it's difficult to do, but it will be very important. And then, to look at the long term neurological outcome. Dr. Greg Hundley:           And I see, Eric, you mentioned the long term, because really in the short term, so within six months, you really didn't see any changes in neurological functional outcome or quality of life. So Manos, just coming back to you. What do you see is the next study that should be performed in this space? Dr. Emmanouil Brilakis: Yeah, I agree actually, with Eric. The next step is, this was an 80 patient study. Right? It's a very small preliminary data, all that opens a new system for evaluation, we're still a very small number of patients. So having a larger number of patients, I think for me, the key thing is to understand the connection. Does this actually cause neurologic symptoms? What does it mean having a microbleed? I think right now, we're still confused on the study. There was not really much impact on the neurologic status of the patient. So for me, the number one thing is, to understand how it impacts the patient's quality of life, the neurologic status. Perhaps more sensitive studies, neurocognitive studies, to understand exactly how it impacts. And then after doing that, I agree with Eric, if this is a bad, something really bad, then we can find different ways to prevent them from happening. Protamine is one of them during the procedure time, and not be a very feasible one. Or it could be interesting to see if different valves, for example, have different propensity for causing those microbleeds. Dr. Greg Hundley: Very nice. Well listeners, we want to thank Dr. Eric Van Belle, from Lille, France, and also, our own associate editor, Dr. Manos Brilakis, from Minneapolis, Minnesota for bringing this very important study, highlighting that one out of four patients undergoing TAVR has cerebral microbleeds before the procedure. And then, after the procedure, one in four patients develop new cerebral microbleeds. And then, procedural and antithrombotic management, and persistence of acquired Von Willebrand factor defects, were associated with the occurrence of these new cerebral microbleeds. Well, on behalf of Carolyn and myself, we want to wish you a great week, and we will catch you next week On the Run. Dr. Greg Hundley:           This program is copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own, and not necessarily those of the editors, or of the American Heart Association. For more, please visit ahajournals.org.

Synopsis: In lieu of a 1-page article, here is the audio version of the book review I wrote on Faith Shattered and Restored: Judaism in the Postmodern Age, by R' Shagar. I don't usually post my book reviews on my blog or record them as podcasts, but I felt like I had to make an exception here, for reasons which I explain in the preface to what is essentially an essay on my first thoughts about R' Shagar's approach. I'll note that while I was making the recording, it dawned on me that this particular essay doesn't really lend itself to an audio version - probably because the sentences are more complex than usual, making it hard to follow by listening - but I went ahead and finished the recording anyway, in case someone finds it valuable.  ----------The Torah content for these two weeks has been sponsored by Ariel Rachmanov, a friend and Mishlei talmid of mine. Ariel works for Keller Williams Real Estate and has generously offered to donate to the Rabbi Schneeweiss Torah Content Fund a percentage of any business that comes his way as a result of this sponsorship, resulting in a Mishleic "win, win, win" scenario for all parties involved. Ariel is based in New York but will be happy to help you meet your real estate needs in all 50 states.----------If you have questions, comments, or feedback, I would love to hear from you! Please feel free to contact me at rabbischneeweiss at gmail.----------If you've gained from what you've learned here, please consider contributing to my Patreon at www.patreon.com/rabbischneeweiss. Alternatively, if you would like to make a direct contribution to the "Rabbi Schneeweiss Torah Content Fund," my Venmo is @Matt-Schneeweiss, and my Zelle and PayPal are mattschneeweiss at gmail.com. Even a small contribution goes a long way to covering the costs of my podcasts, and will provide me with the financial freedom to produce even more Torah content for you.If you would like to sponsor a day's or a week's worth of content, or if you are interested in enlisting my services as a teacher or tutor, you can reach me at rabbischneeweiss at gmail.com. Thank you to my listeners for listening, thank you to my readers for reading, and thank you to my supporters for supporting my efforts to make Torah ideas available and accessible to everyone.----------Patreon: patreon.com/rabbischneeweissYouTube Channel: youtube.com/rabbischneeweissBlog: kolhaseridim.blogspot.com/"The Mishlei Podcast": mishlei.buzzsprout.com"The Stoic Jew" Podcast: thestoicjew.buzzsprout.com"Rambam Bekius" Podcast: rambambekius.buzzsprout.com"Machshavah Lab" Podcast: machshavahlab.buzzsprout.com"The Tefilah Podcast": tefilah.buzzsprout.comWhatsApp Group: https://chat.whatsapp.com/GEB1EPIAarsELfHWuI2k0HAmazon Wishlist: amazon.com/hz/wishlist/ls/Y72CSP86S24W?ref_=wl_sharel

For two years we've heard about the evolution of work with workers largely dictating the new terms. But as the economy continues to evolve what does the current job landscape look like? Is now a good time to be looking for a job? How do you develop a relationship with a recruiter? All of these questions and more as we chat with Wasim Munayyer, CEO and owner of the Munayyer Group, who helps logistics and technology companies find talent. Connect with Wasim Munayyer on LinkedIn. Everything is Logistics is hosted by Blythe Brumleve, founder of Digital Dispatch where we help freight companies get online and grow. Check out our top shows to fix your website and fix your marketing. Alternatively, you can search by topic and check out all our past episodes of the podcast—right on our website.Connect with Blythe on Linkedin, YouTube, and TikTokDisclosure: The Munayyer Group is a sponsor of Cyberly--which is where this segment comes from. Go show them some love so we can keep bringing you these awesome conversations! assets: https://drive.google.com/drive/folders/1bj8JAkPD-RebT2KEudjsC1AhR4cx9d-7?usp=sharingad reads: https://docs.google.com/document/d/1qfLonVH4A488H5bcQHyPtVIxxFHVMS0EbT3mJq5f2ss/edit

Okay, that's a bit reductive. Laundry too! 0:10 - Still playing Persona 5. Still enjoying Persona 5. Still complaining about Persona 5. 28:35 - Comic Con was this week. No one told Warner Bros. If you missed Saturday's live broadcast of Molehill Mountain, you can watch the video replay on YouTube.  Alternatively, you can catch audio versions of the show on iTunes. Molehill Mountain streams live at 7p PST every Saturday night! Credits: Molehill Mountain is hosted by Andrew Eisen.  Music in the show includes “Albino” by Brian Boyko. It is in the public domain and free to use. Molehill Mountain logo by Scott Hepting. Chat Transcript: 7:01 PMCafeFox​sup 7:01 PMCafeFox​get any rain where you are yet? 7:03 PMSheekago​Good evening Andrew and all 7:07 PMSheekago​Is she hibernating or in a coma? 7:07 PMSheekago​Does she need to be kissed by Prince Charming? 7:07 PMJared Knisely​ah yes, a weekly accordance of andrew ranting about persona's design 7:10 PMJared Knisely​you can date here to my knowledge 7:11 PMJared Knisely​"her" 7:11 PMSheekago​@Jared Knisely well, it's his first Persona game and it's what he's playing, so it makes sense. Once I start playing Persona, I'm sure I'll be looking for others to talk about it with. 7:11 PMJared Knisely​i havent played it, just telling him that i belive that he can do it 7:20 PMJared Knisely​i've seen some of the confession scenes and i believe she is in it but could be wrong 7:22 PMmatthew wilson​I think smt will be your thing if what you want on the dongen crawler 7:23 PManime momo​Have you did anything different lately Andrew ,you look really handsome today (: 7:24 PMJared Knisely​there is a harem playthrough 7:25 PMJared Knisely​watch anything over the week? 7:27 PMmatthew wilson​so something horrer related than 7:28 PMmatthew wilson​eorovision is wild 7:28 PMmatthew wilson​its bizare 7:28 PMCafeFox​I so want to watch a Eurovision 7:29 PMJared Knisely​that will be 1 my time] 7:29 PMaddictedtochaos​Do you know what date Extra Life is this year? 7:32 PMJared Knisely​yes 7:32 PMJared Knisely​bad trailer come out in it 7:33 PMmatthew wilson​I know disney reveled a ton of mcu stuff tonight 7:33 PMJared Knisely​rings of power too 7:33 PMJared Knisely​thats the bad one 7:33 PMmatthew wilson​though tbf the only intreasting thing to me about mcu phase 5 is secret war 7:38 PMmatthew wilson​it looks very monty python, which hot take is the corect way to handle dnd 7:38 PMCafeFox​did you see the tweet i made, Andrew. trailer for a trailer 7:39 PMaddictedtochaos​Have you seen “The Boys”? 7:40 PMmatthew wilson​like a dnd movie has to be a semi comady b/c getting crit fails (roll a 1) is very much part of dnd 7:50 PMCafeFox​yeah it was an @. trailer for the movie had a teaser for it before 7:51 PMmatthew wilson​ouch 7:52 PMmatthew wilson​a 1 in 8000 chance concrats 7:52 PMmatthew wilson​ /s 7:53 PMSheekago​the dice were crooked! 7:54 PMmatthew wilson​but yeah their better be atleat 1 crit miss 7:57 PMmatthew wilson​like I said the only intreasting thingg in phase 5 is secrat war 7:57 PMSheekago​Spider-Man: The Senior Years. In this issue, Spidey vs Social Security Man. Spidey needs his Social security check! 8:01 PMCafeFox​tiny toons is coming back! nice

Okay, that’s a bit reductive. Laundry too! 0:10 – Still playing Persona 5. Still enjoying Persona 5. Still complaining about Persona 5. 28:35 – Comic Con was this week. No one told Warner Bros. If you missed Saturday's live broadcast of Molehill Mountain, you can watch the video replay on YouTube.  Alternatively, you can catch audio ...Continue reading ‘Molehill Mountain Episode 297 – Dating Your Teacher For Coffee’ »

FIR is back with Episode 442 as the FUTTIES promo rolls on in FIFA 22. Join Wimb & Shaqattack for a full round up of all the latest content including our thoughts on whether Barella is the best SBC of the year, plus our views on Torres, Sow, Chiesa, Pato & much more. We also give some brief thoughts on FIFA 23 so far, including the opening gameplay pitch notes. Remember we need your help to grow our new YouTube channel, all it takes is for you to subscribe for free, and it will help more people find us! Also, if you want help improving your game please check out FUTCoaching.com and to help support the show and get a range of benefits including episodes ad-free and early, head to patreon.com/futinreview. Alternatively, please leave us a 5-star review over at Apple to help spread the word of the show, or you can also leave us a review on Spotify! --- Send in a voice message: https://anchor.fm/futinreview/message

Synopsis: This is the audio version of the 1-page article I wrote, entitled Masei: How to Read the Travels of Bnei Yisrael, in which we learn the Rambam's answer to the question, "Why does the Torah 'waste' so many pesukim by listing all 42 encampments of Bnei Yisrael in the Wilderness?" and discuss its implications for how we read this perek. ----------The Torah content for this week has been sponsored by Ellis and Janice Cohen in memory of Rabbi Moskowitz zt"l.----------If you have questions, comments, or feedback, I would love to hear from you! Please feel free to contact me at rabbischneeweiss at gmail.----------If you've gained from what you've learned here, please consider contributing to my Patreon at www.patreon.com/rabbischneeweiss. Alternatively, if you would like to make a direct contribution to the "Rabbi Schneeweiss Torah Content Fund," my Venmo is @Matt-Schneeweiss, and my Zelle and PayPal are mattschneeweiss at gmail.com. Even a small contribution goes a long way to covering the costs of my podcasts, and will provide me with the financial freedom to produce even more Torah content for you.If you would like to sponsor a day's or a week's worth of content, or if you are interested in enlisting my services as a teacher or tutor, you can reach me at rabbischneeweiss at gmail.com. Thank you to my listeners for listening, thank you to my readers for reading, and thank you to my supporters for supporting my efforts to make Torah ideas available and accessible to everyone.----------Patreon: patreon.com/rabbischneeweissYouTube Channel: youtube.com/rabbischneeweissBlog: kolhaseridim.blogspot.com/"The Mishlei Podcast": mishlei.buzzsprout.com"The Stoic Jew" Podcast: thestoicjew.buzzsprout.com"Rambam Bekius" Podcast: rambambekius.buzzsprout.com"Machshavah Lab" Podcast: machshavahlab.buzzsprout.com"The Tefilah Podcast": tefilah.buzzsprout.comWhatsApp Group: https://chat.whatsapp.com/GEB1EPIAarsELfHWuI2k0HAmazon Wishlist: amazon.com/hz/wishlist/ls/Y72CSP86S24W?ref_=wl_sharel

You might have witnessed a viral video going around that showed a man in the jungle harvesting tiny beatles into a red paste. Turns out that red paste is used to make red lipstick and is also the main ingredient for red food coloring. In today's episode, we're diving into that process of lipstick making along with the challenges lipstick brands are facing on the manufacturing and distribution side of things---which plays right into another fun fact you'll learn which is the Lipstick Index. Watch the TikTok of this topic where I talk about the logistics of lipstick and then a follow-up video where I break down the Lipstick IndexCheck out other episodes from our "The Logistics of......" seriesEverything is Logistics is hosted by Blythe Brumleve, founder of Digital Dispatch where we help freight companies get online and grow. Check out our top shows to fix your website and fix your marketing. Alternatively, you can search by topic and check out all our past episodes of the podcast—right on our website.Connect with Blythe on Linkedin, YouTube, and TikTok

Synopsis: This is the audio version of the 1-page article I wrote, entitled Why Talk About Other Religions? which is a response to a series of questions asked by a friend of mine about why I made a statement comparing Judaism to other religions in one of my articles last week. Related Content:- Minhag Mythbusters: Does a Husband Sing Eishes Chayil for His Wife?- Is Judaism a Religion? (Version 2.0)- Hillel and the Converts----------The Torah content for this week has been sponsored by Ellis and Janice Cohen in memory of Rabbi Moskowitz zt"l.----------If you have questions, comments, or feedback, I would love to hear from you! Please feel free to contact me at rabbischneeweiss at gmail.----------If you've gained from what you've learned here, please consider contributing to my Patreon at www.patreon.com/rabbischneeweiss. Alternatively, if you would like to make a direct contribution to the "Rabbi Schneeweiss Torah Content Fund," my Venmo is @Matt-Schneeweiss, and my Zelle and PayPal are mattschneeweiss at gmail.com. Even a small contribution goes a long way to covering the costs of my podcasts, and will provide me with the financial freedom to produce even more Torah content for you.If you would like to sponsor a day's or a week's worth of content, or if you are interested in enlisting my services as a teacher or tutor, you can reach me at rabbischneeweiss at gmail.com. Thank you to my listeners for listening, thank you to my readers for reading, and thank you to my supporters for supporting my efforts to make Torah ideas available and accessible to everyone.----------Patreon: patreon.com/rabbischneeweissYouTube Channel: youtube.com/rabbischneeweissBlog: kolhaseridim.blogspot.com/"The Mishlei Podcast": mishlei.buzzsprout.com"The Stoic Jew" Podcast: thestoicjew.buzzsprout.com"Rambam Bekius" Podcast: rambambekius.buzzsprout.com"Machshavah Lab" Podcast: machshavahlab.buzzsprout.com"The Tefilah Podcast": tefilah.buzzsprout.comWhatsApp Group: https://chat.whatsapp.com/GEB1EPIAarsELfHWuI2k0HAmazon Wishlist: amazon.com/hz/wishlist/ls/Y72CSP86S24W?ref_=wl_sharel

In this episode of the Maven Money Personal Finance Podcast… Andy encourages you to take ACTION.   Links:    Humans Under Management   Andy Hart   Patreon   Leave a review!     Don't forget to check out the Maven Adviser website for more great content.   So sit back and enjoy unrivalled words of wisdom from Andy Hart - host of the UK's premier personal finance show.   Is there a topic you'd like Andy to cover? We'd love to hear from you! Contact Andy Hart directly with any comments / feedback on team@mavenadviser.com. Alternatively you can reach out on Twitter @MavenAdviser. 

Hello Futties! John aka FUTcoaching takes a quick break from his vacation to give us a deep dive into the first in depth gameplay pitch notes for FIFA 23. We highlight the key changes and give you tips and hints to try and get ready for September. We'll return with another show in the next few days to round up the latest FIFA 22 content so please stay tuned to the show feed! Remember we need your help to grow our new YouTube channel, all it takes is for you to subscribe for free, and it will help more people find us! Also, if you want help improving your game please check out FUTCoaching.com and to help support the show and get a range of benefits including episodes ad-free and early, head to patreon.com/futinreview. Alternatively, please leave us a 5-star review over at Apple to help spread the word of the show, or you can also leave us a review on Spotify! --- Send in a voice message: https://anchor.fm/futinreview/message

Synopsis: My initial answer to this question prompted by a letter from Seneca was, “No!” but then I realized that the question is more nuanced than I thought. The answer and its implications are not as simple as they seem. In this episode I offer some thoughts, examples, and questions on this topic in light of a pasuk in Mishlei cited by the Rambam and elucidated by a midrash.Sources:- Seneca, Letter #13- Rambam: Mishneh Torah, Sefer ha'Mada, Hilchos Deios 6:1- Midrash on Mishlei 13:20----------The Torah content for this week has been sponsored by Ellis and Janice Cohen in memory of Rabbi Moskowitz zt"l.----------If you have questions, comments, or feedback, I would love to hear from you! Please feel free to contact me at rabbischneeweiss at gmail.----------If you've gained from what you've learned here, please consider contributing to my Patreon at www.patreon.com/rabbischneeweiss. Alternatively, if you would like to make a direct contribution to the "Rabbi Schneeweiss Torah Content Fund," my Venmo is @Matt-Schneeweiss, and my Zelle/Chase QuickPay and PayPal are mattschneeweiss at gmail.com. Even a small contribution goes a long way to covering the costs of my podcasts, and will provide me with the financial freedom to produce even more Torah content for you.If you would like to sponsor an article, shiur, or podcast episode, or if you are interested in enlisting my services as a teacher or tutor, you can reach me at rabbischneeweiss at gmail.com. Thank you to my listeners for listening, thank you to my readers for reading, and thank you to my supporters for supporting my efforts to make Torah ideas available and accessible to everyone.----------patreon.com/rabbischneeweissyoutube.com/rabbischneeweisskolhaseridim.blogspot.com/mishlei.buzzsprout.comthestoicjew.buzzsprout.comrambambekius.buzzsprout.commachshavahlab.buzzsprout.comtefilah.buzzsprout.comhttps://chat.whatsapp.com/GEB1EPIAarsELfHWuI2k0Hamazon.com/hz/wishlist/ls/Y72CSP86S24W?ref_=wl_sharelSupport the show

On last week's show we talked about the digital marketing strategies for the top carriers in the US–so this week we're doing the same for 3PLs. By looking at their websites and social media, we can get a good idea of how these companies strategize their marketing efforts so you can apply what works for you to your own company.Armstrong and Associates Top 3PLs ListHow the top carriers treat digital marketingEverything is Logistics is hosted by Blythe Brumleve, founder of Digital Dispatch where we help freight companies get online and grow. Check out our top shows to fix your website and fix your marketing. Alternatively, you can search by topic and check out all our past episodes of the podcast—right on our website.Connect with Blythe on Linkedin, YouTube, and TikTok

In 2013, director Edgar Wright concluded his Three Flavours Cornetto Trilogy, all co-written with Simon Pegg, produced by Nira Park, and starring Pegg and Nick Frost. Alternatively called the Blood and Ice Cream Trilogy, the first two films, Shaun of the Dead and Hot Fuzz, riffed on  zombie movies and the buddy cop genre. For the final entry in the trilogy, Wright and Pegg tackled sci-fi alien invasion flicks like Invasion of the Body Snatchers with a film centered on five high school mates reuniting for a pub crawl in their hometown. Also featuring Paddy Considine, Martin Freeman, Eddie Marsan, Rosamund Pike, and Pierce Brosnan, the film wraps up the trilogy's themes of individualism vs. the collective and the dangers of perpetual adolescence. Now we're bending our elbows and crossing over with Westworld Weekly to follow the boys from their first sip all the way to The World's End. But in the sober light of day, is this movie good to the last drop?     For more geeky podcasts visit GonnaGeek.com   You can find us on iTunes under ''Legends Podcast''. Please subscribe and give us a positive review. You can also follow us on Twitter @LegendsPodcast or even better, send us an e-mail: LegendsPodcastS@gmail.com You can find all our contact information here on the Network page of GonnaGeek.com Our complete archive is always available at www.legendspodcast.com, www.legendspodcast.libsyn.com

Synopsis: This is the audio version of the 1-page article I wrote, entitled Sefer Mishlei's Jargon-Filled Introduction (Mishlei 1:1-6). I recently initiated a project to learn Mishlei from the beginning again (as opposed to my usual practice of learning and teaching pesukim from Chapter 10 and on). I can't promise that I'll write up ALL my findings as articles, but I decided to make an attempt with this first set of pesukim. We'll how things go from here. ----------The Torah content for this week has been sponsored by Ellis and Janice Cohen in memory of Rabbi Moskowitz zt"l.----------If you have questions, comments, or feedback, I would love to hear from you! Please feel free to contact me at rabbischneeweiss at gmail.----------If you've gained from what you've learned here, please consider contributing to my Patreon at www.patreon.com/rabbischneeweiss. Alternatively, if you would like to make a direct contribution to the "Rabbi Schneeweiss Torah Content Fund," my Venmo is @Matt-Schneeweiss, and my Zelle and PayPal are mattschneeweiss at gmail.com. Even a small contribution goes a long way to covering the costs of my podcasts, and will provide me with the financial freedom to produce even more Torah content for you.If you would like to sponsor a day's or a week's worth of content, or if you are interested in enlisting my services as a teacher or tutor, you can reach me at rabbischneeweiss at gmail.com. Thank you to my listeners for listening, thank you to my readers for re